Clinical Trial Update: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Open-label extension study results for CDP870 in rheumatoid arthritis completed Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CDP870 (certolizumab pegol)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED